Trial Profile
A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy injection ALK Abello (Primary)
- Indications Allergic asthma; Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Healthcare
- 23 Jun 2016 Status changed from recruiting to completed.
- 09 Nov 2015 New trial record